The company has already received orphan drug designation from the European Medicines Agency for Graspa as a treatment for pancreatic cancer.
Erytech Pharma co-founder, vice president and chief scientific officer Yann Godfrin said Graspa showed good safety and tolerability in these particularly fragile patients, whereas other clinical studies have shown significant toxicity with forms of asparaginase.
Erytech Pharma co-founder and chairman Pierre-Olivier Goineau said with Graspa’s efficacy and tolerance profile, they are expecting to widen its scope for appropriate use – particularly in solid tumors.